FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody-drug conjugate for treatment of a malignant neoplasm expressing Her2. Also disclosed is a method for producing said conjugate, a method for treating a malignant tumor using said conjugate, and using said conjugate to obtain a drug for treatment of a malignant tumor expressing HER2 in a patient. A composition containing the specified conjugate, a nucleic acid encoding an antibody used in the preparation of the specified conjugate, an expression vector, and a host cell containing the specified nucleic acid are disclosed.
EFFECT: invention makes it possible to effectively treat malignant neoplasm expressing Her2.
51 cl, 27 tbl, 30 dwg, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| ANTIBODIES AGAINST EDB AND ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2758632C2 |
| ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2806049C2 |
| ANTIBODY-DRUG CONJUGATES CONTAINING HERBOXYDIENE-BASED SPLICING MODULATOR, AND METHODS OF USE THEREOF | 2019 |
|
RU2820607C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
| ANTIBODY-DRUG CONJUGATE, INTERMEDIATE FOR ITS PRODUCTION, METHOD OF ITS PRODUCTION AND ITS USE | 2020 |
|
RU2800137C1 |
| BISPECIFIC ANTIGEN-BINDING CONSTRUCTS AGAINST HER2 | 2014 |
|
RU2737882C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
